Genomic  ||| S:0 E:8 ||| JJ
endophenotypes  ||| S:8 E:23 ||| NN
of  ||| S:23 E:26 ||| IN
attention  ||| S:26 E:36 ||| NN
deficit  ||| S:36 E:44 ||| NN
hyperactivity  ||| S:44 E:58 ||| FW
disorder  ||| S:58 E:67 ||| FW
Attention  ||| S:67 E:77 ||| FW
deficit  ||| S:77 E:85 ||| FW
hyperactivity  ||| S:85 E:99 ||| FW
disorder  ||| S:99 E:108 ||| FW
( ||| S:108 E:109 ||| -LRB-
ADHD ||| S:109 E:113 ||| NNP
)  ||| S:113 E:115 ||| -RRB-
is  ||| S:115 E:118 ||| VBZ
a  ||| S:118 E:120 ||| DT
remarkably  ||| S:120 E:131 ||| JJ
heterogeneous  ||| S:131 E:145 ||| JJ
neurobiological  ||| S:145 E:161 ||| JJ
disorder ||| S:161 E:169 ||| NN
.  ||| S:169 E:171 ||| .
This  ||| S:171 E:176 ||| DT
characteristic  ||| S:176 E:191 ||| NN
is  ||| S:191 E:194 ||| VBZ
aetiologically  ||| S:194 E:209 ||| JJ
mediated  ||| S:209 E:218 ||| NN
by  ||| S:218 E:221 ||| IN
genetic  ||| S:221 E:229 ||| JJ
and  ||| S:229 E:233 ||| CC
environmental  ||| S:233 E:247 ||| JJ
factors ||| S:247 E:254 ||| NNS
.  ||| S:254 E:256 ||| .
Numerous  ||| S:256 E:265 ||| JJ
studies  ||| S:265 E:273 ||| NNS
have  ||| S:273 E:278 ||| VBP
shown  ||| S:278 E:284 ||| VBN
that  ||| S:284 E:289 ||| IN
different  ||| S:289 E:299 ||| JJ
genes  ||| S:299 E:305 ||| NNS
play  ||| S:305 E:310 ||| VBP
a  ||| S:310 E:312 ||| DT
moderate  ||| S:312 E:321 ||| JJ
but  ||| S:321 E:325 ||| CC
complex  ||| S:325 E:333 ||| JJ
role  ||| S:333 E:338 ||| NN
in  ||| S:338 E:341 ||| IN
the  ||| S:341 E:345 ||| DT
aetiology  ||| S:345 E:355 ||| NN
of  ||| S:355 E:358 ||| IN
ADHD ||| S:358 E:362 ||| NNP
.  ||| S:362 E:364 ||| .
Significant  ||| S:364 E:376 ||| JJ
associations  ||| S:376 E:389 ||| NNS
have  ||| S:389 E:394 ||| VBP
been  ||| S:394 E:399 ||| VBN
identified  ||| S:399 E:410 ||| VBN
with  ||| S:410 E:415 ||| IN
several  ||| S:415 E:423 ||| JJ
candidate  ||| S:423 E:433 ||| NN
genes  ||| S:433 E:439 ||| NNS
for  ||| S:439 E:443 ||| IN
this  ||| S:443 E:448 ||| DT
disorder ||| S:448 E:456 ||| NN
,  ||| S:456 E:458 ||| ,
including  ||| S:458 E:468 ||| VBG
DAT1 ||| S:468 E:472 ||| NNP
,  ||| S:472 E:474 ||| ,
DRD4 ||| S:474 E:478 ||| NNP
,  ||| S:478 E:480 ||| ,
DRD5 ||| S:480 E:484 ||| NNP
,  ||| S:484 E:486 ||| ,
5HTT ||| S:486 E:490 ||| NNP
,  ||| S:490 E:492 ||| ,
HTR1B  ||| S:492 E:498 ||| NNP
or  ||| S:498 E:501 ||| CC
SNAP25 ||| S:501 E:507 ||| NNP
.  ||| S:507 E:509 ||| .
The  ||| S:509 E:513 ||| DT
neurocognitive  ||| S:513 E:528 ||| JJ
models  ||| S:528 E:535 ||| NNS
of  ||| S:535 E:538 ||| IN
ADHD  ||| S:538 E:543 ||| NNP
have  ||| S:543 E:548 ||| VBP
been  ||| S:548 E:553 ||| VBN
largely  ||| S:553 E:561 ||| RB
based  ||| S:561 E:567 ||| VBN
on  ||| S:567 E:570 ||| IN
the  ||| S:570 E:574 ||| DT
findings  ||| S:574 E:583 ||| NNS
from  ||| S:583 E:588 ||| IN
neuroimaging  ||| S:588 E:601 ||| JJ
studies  ||| S:601 E:609 ||| NNS
conducted  ||| S:609 E:619 ||| VBN
in  ||| S:619 E:622 ||| IN
patients  ||| S:622 E:631 ||| NNS
with  ||| S:631 E:636 ||| IN
ADHD ||| S:636 E:640 ||| NNP
,  ||| S:640 E:642 ||| ,
when  ||| S:642 E:647 ||| WRB
establishing  ||| S:647 E:660 ||| VBG
hypotheses  ||| S:660 E:671 ||| JJ
capable  ||| S:671 E:679 ||| JJ
of  ||| S:679 E:682 ||| IN
explaining  ||| S:682 E:693 ||| VBG
the  ||| S:693 E:697 ||| DT
clinical  ||| S:697 E:706 ||| JJ
features  ||| S:706 E:715 ||| NNS
that  ||| S:715 E:720 ||| WDT
are  ||| S:720 E:724 ||| VBP
observed ||| S:724 E:732 ||| VBN
.  ||| S:732 E:734 ||| .
From  ||| S:734 E:739 ||| IN
a  ||| S:739 E:741 ||| DT
neurobiological  ||| S:741 E:757 ||| JJ
point  ||| S:757 E:763 ||| NN
of  ||| S:763 E:766 ||| IN
view ||| S:766 E:770 ||| NN
,  ||| S:770 E:772 ||| ,
the  ||| S:772 E:776 ||| DT
genetic  ||| S:776 E:784 ||| JJ
architecture  ||| S:784 E:797 ||| NN
of  ||| S:797 E:800 ||| IN
these  ||| S:800 E:806 ||| DT
patients  ||| S:806 E:815 ||| NNS
or  ||| S:815 E:818 ||| CC
the  ||| S:818 E:822 ||| DT
interaction  ||| S:822 E:834 ||| NN
of  ||| S:834 E:837 ||| IN
the  ||| S:837 E:841 ||| DT
above-mentioned  ||| S:841 E:857 ||| JJ
genes  ||| S:857 E:863 ||| NNS
should  ||| S:863 E:870 ||| MD
at  ||| S:870 E:873 ||| IN
least  ||| S:873 E:879 ||| JJS
partially  ||| S:879 E:889 ||| JJ
account  ||| S:889 E:897 ||| NN
for  ||| S:897 E:901 ||| IN
the  ||| S:901 E:905 ||| DT
neuroanatomical  ||| S:905 E:921 ||| NN
and  ||| S:921 E:925 ||| CC
neuropsychological  ||| S:925 E:944 ||| JJ
findings  ||| S:944 E:953 ||| NNS
observed ||| S:953 E:961 ||| VBD
,  ||| S:961 E:963 ||| ,
which  ||| S:963 E:969 ||| WDT
explains  ||| S:969 E:978 ||| VBZ
the  ||| S:978 E:982 ||| DT
axiomatic  ||| S:982 E:992 ||| JJ
antithesis  ||| S:992 E:1003 ||| NN
in  ||| S:1003 E:1006 ||| IN
the  ||| S:1006 E:1010 ||| DT
title ||| S:1010 E:1015 ||| NN
.  ||| S:1015 E:1017 ||| .
Nevertheless ||| S:1017 E:1029 ||| RB
,  ||| S:1029 E:1031 ||| ,
the  ||| S:1031 E:1035 ||| DT
results  ||| S:1035 E:1043 ||| NNS
of  ||| S:1043 E:1046 ||| IN
studies  ||| S:1046 E:1054 ||| NNS
into  ||| S:1054 E:1059 ||| IN
the  ||| S:1059 E:1063 ||| DT
relationship  ||| S:1063 E:1076 ||| NN
between  ||| S:1076 E:1084 ||| IN
the  ||| S:1084 E:1088 ||| DT
genotyping  ||| S:1088 E:1099 ||| NN
and  ||| S:1099 E:1103 ||| CC
the  ||| S:1103 E:1107 ||| DT
neuroimaging  ||| S:1107 E:1120 ||| NN
or  ||| S:1120 E:1123 ||| CC
psychological  ||| S:1123 E:1137 ||| JJ
findings  ||| S:1137 E:1146 ||| NNS
are  ||| S:1146 E:1150 ||| VBP
scarce  ||| S:1150 E:1157 ||| JJ
and  ||| S:1157 E:1161 ||| CC
contradictory ||| S:1161 E:1174 ||| JJ
.  ||| S:1174 E:1176 ||| .
The  ||| S:1176 E:1180 ||| DT
methodological  ||| S:1180 E:1195 ||| JJ
differences  ||| S:1195 E:1207 ||| NNS
in  ||| S:1207 E:1210 ||| IN
the  ||| S:1210 E:1214 ||| DT
volumetric  ||| S:1214 E:1225 ||| JJ
analyses ||| S:1225 E:1233 ||| NNS
,  ||| S:1233 E:1235 ||| ,
the  ||| S:1235 E:1239 ||| DT
sizes  ||| S:1239 E:1245 ||| NN
of  ||| S:1245 E:1248 ||| IN
the  ||| S:1248 E:1252 ||| DT
populations  ||| S:1252 E:1264 ||| NNS
studied ||| S:1264 E:1271 ||| VBN
,  ||| S:1271 E:1273 ||| ,
the  ||| S:1273 E:1277 ||| DT
neuropsychological  ||| S:1277 E:1296 ||| JJ
batteries  ||| S:1296 E:1306 ||| NNS
that  ||| S:1306 E:1311 ||| WDT
are  ||| S:1311 E:1315 ||| VBP
used ||| S:1315 E:1319 ||| VBN
,  ||| S:1319 E:1321 ||| ,
the  ||| S:1321 E:1325 ||| DT
presence  ||| S:1325 E:1334 ||| NN
of  ||| S:1334 E:1337 ||| IN
previous  ||| S:1337 E:1346 ||| JJ
pharmacological  ||| S:1346 E:1362 ||| JJ
treatment  ||| S:1362 E:1372 ||| NN
or  ||| S:1372 E:1375 ||| CC
comorbidity  ||| S:1375 E:1387 ||| NNS
could  ||| S:1387 E:1393 ||| MD
account  ||| S:1393 E:1401 ||| VB
for  ||| S:1401 E:1405 ||| IN
these  ||| S:1405 E:1411 ||| DT
results ||| S:1411 E:1418 ||| NNS
.  ||| S:1418 E:1420 ||| .
